Show simple item record

dc.contributor.authorAgaimy, A
dc.contributor.authorFonseca, I
dc.contributor.authorMartins, C
dc.contributor.authorThway, K
dc.contributor.authorBarrette, R
dc.contributor.authorHarrington, KJ
dc.contributor.authorHartmann, A
dc.contributor.authorFrench, CA
dc.contributor.authorFisher, C
dc.date.accessioned2018-04-27T14:10:54Z
dc.date.issued2018-07-01
dc.identifier.citationThe American journal of surgical pathology, 2018, 42 (7), pp. 877 - 884
dc.identifier.issn0147-5185
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1661
dc.identifier.eissn1532-0979
dc.identifier.doi10.1097/pas.0000000000001046
dc.description.abstractNUT carcinoma (NC) represents a rare subset of highly aggressive poorly differentiated carcinomas characterized by rearrangement of the NUT (aka NUTM1, nuclear protein in testis) gene, most commonly fused to BRD4. Originally described as a mediastinal/thymic malignancy, NC has been reported at a variety of anatomic regions including the upper and lower aerodigestive tract. To date, only 7 NC cases of probable salivary gland origin have been reported. We herein describe 3 new cases (all affecting the parotid gland) in 2 women (39- and 55-y old) and 1 man (35-y old). Histologic examination showed poorly differentiated neoplasms composed of poorly cohesive small-sized to medium-sized cells with variable squamoid cell component that was focal and abrupt. Immunohistochemistry showed uniform expression of p63 and distinctive punctate expression of the NUT antigen in the tumor cell nuclei. Review of the reported salivary gland NC cases (total, 10) showed a male:female ratio of 1.5:1 and an age range of 12 to 55 years (median, 29 y). Site of the primary tumor was the parotid (7), sublingual (2), and submandibular (1) glands. All presented as rapidly growing masses treated by surgery followed by adjuvant radiotherapy/chemotherapy. Initial nodal status was positive in 8/10. At last follow-up (1 to 24 mo; median, 5 mo), 7/10 patients died of disease at a median of 5.5 months (1 to 24 mo) and only 2 were disease free at 7 and 14 months. Of 9 cases with genetic data, the fusion partner was BRD4 (n=7), non-BRD4/3 (n=1), or undetermined (n=1). None of 306 carcinomas spanning the spectrum of salivary carcinoma types screened by NUT immunohistochemistry was positive. This is the first small series on salivary NC highlighting the importance to include this rare disease in the differential diagnosis of poorly differentiated salivary gland carcinomas and in cases of presumable poorly differentiated carcinoma of unknown origin.
dc.formatPrint
dc.format.extent877 - 884
dc.languageeng
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectCarcinoma
dc.subjectParotid Neoplasms
dc.subjectGenetic Predisposition to Disease
dc.subjectNeoplasm Proteins
dc.subjectNuclear Proteins
dc.subjectTranscription Factors
dc.subjectBiopsy
dc.subjectTreatment Outcome
dc.subjectImmunohistochemistry
dc.subjectIn Situ Hybridization, Fluorescence
dc.subjectGene Fusion
dc.subjectCell Differentiation
dc.subjectGene Rearrangement
dc.subjectPhenotype
dc.subjectAdult
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectBiomarkers, Tumor
dc.titleNUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas.
dc.typeJournal Article
rioxxterms.versionofrecord10.1097/pas.0000000000001046
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe American journal of surgical pathology
pubs.issue7
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume42
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record